Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA)

Diagnostic Microbiology and Infectious Disease

Volumn 56, Issue 1, 2006, Pages 57-62

  Rhomberg, Paul R ^a   Fritsche, Thomas R ^a   Sader, Helio S ^a   Jones, Ronald N ^a,b  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Carbepenems; ICU; Meropenem; MYSTIC; Resistance; Surveillance

Indexed keywords

ANTIBIOTIC AGENT; AZTREONAM; CARBAPENEM DERIVATIVE; CEFEPIME; CEFTAZIDIME; CEFTIZOXIME; CEFTRIAXONE; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; COMPARATIVE STUDY; CONTROLLED STUDY; ENTEROBACTERIACEAE; GRAM NEGATIVE BACTERIUM; INTENSIVE CARE UNIT; NONHUMAN; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; CARBAPENEMS; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIA; HUMANS; INTENSIVE CARE UNITS; LINEAR MODELS; LONGITUDINAL STUDIES; MICROBIAL SENSITIVITY TESTS; POPULATION SURVEILLANCE; THIENAMYCINS;

EID: 33747808567     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2005.12.009     Document Type: Article

References (21)

1. Badia J.R., Soy D., Adrover M., Ferrer M., Sarasa M., Alarcon A., Codina C., and Torres A. Disposition of instilled versus nebulized tobramycin and imipenem in ventilated intensive care unit (ICU) patients. J. Antimicrob. Chemother. 54 (2004) 508-514
2. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Document M100-S15 (2005), CLSI, Wayne, PA
3. Cornaglia G., Hryniewicz W., Jarlier V., Kahlmeter G., Mittermayer H., Stratchounski L., and Baquero F. European recommendations for antimicrobial resistance surveillance. Clin. Microbiol. Infect. 10 (2004) 349-383
4. Fridkin S.K., Edwards J.R., Tenover F.C., Gaynes R.P., and McGowan Jr. J.E. Antimicrobial resistance prevalence rates in hospital antibiograms reflect prevalence rates among pathogens associated with hospital-acquired infections. Clin. Infect. Dis. 33 (2001) 324-330
5. Goossens H. Susceptibility of multi-drug-resistant Pseudomonas aeruginosa in intensive care units: results from the European MYSTIC study group. Clin. Microbiol. Infect. 9 (2003) 980-983
6. Hoogkamp-Korstanje J.A.A., Roelofs-Willemse J., and the Susceptibility Surveillance Study Group. Antimicrobial resistance in Gram-negative bacteria from intensive care units and urology services. A nationwide study in The Netherlands 1995-2000. Intern. J. Antimicrob. Agents 21 (2003) 547-556
7. Ibrahim E.H., Sherman G., Ward S., Fraser V.J., and Kollef M.H. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 118 (2000) 146-155
8. Jones R.N., and Masterton R. Determining the value of antimicrobial surveillance programs. Diagn. Microbiol. Infect. Dis. 41 (2001) 171-175
9. Jones M.E., Drughi D.C., Thornsberry C., Karlowsky J.A., Sahm D.F., and Wenzel R.P. Emerging resistance among bacterial pathogens in the intensive care unit-a European and North American surveillance study (2000-2002). Ann. Clin. Microbiol. Antimicrob. 3 (2004) 14
10. Kahlmeter G., and Brown D.F. Resistance surveillance studies-comparability of results and quality assurance of methods. J. Antimicrob. Chemother. 50 (2002) 775-777
11. Karlowsky J.A., Jones M.E., Draghi D.C., Thornsberry C., Sahm D.F., and Volturo G.A. Prevalence and antimicrobial susceptibilities of bacteria isolated from blood cultures of hospitalized patients in the United States in 2002. Ann. Clin. Microbiol. Antimicrob. 3 (2004) 7
12. Kollef M.H. Appropriate empiric antimicrobial therapy of nosocomial pneumonia; the role of carbapenems. Respir. Care 49 (2004) 1530-1541
13. Livermore D.M. The need for new antibiotics. Clin. Microbiol. Infect. 10 Suppl 4 (2004) 1-9
14. Mendes C., Turner P.J., and the MYSTIC Study Group (Europe). Unit differences in pathogen occurrence arising from the MYSTIC Program European database (1997-2000). Diagn. Microbiol. Infect. Dis. 41 (2001) 191-196
15. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Document M7-A6 (2003), NCCLS, Wayne, PA
16. Neuhauser M.M., Weinstein R.A., Rydman R., Danziger L.H., Karam G., and Quinn J.P. Antibiotic resistance among Gram-negative bacilli in US intensive care units. JAMA 289 (2003) 885-888
17. Pfaller M.A., Jones R.N., Biedenbach D.J., and MYSTIC Study Group (USA). Antimicrobial resistance trends in medical centers using carbapenems: report of 1999 and 2000 results from the MYSTIC Program (USA). Diagn. Microbiol. Infect. Dis. 41 (2001) 177-182
18. Rhomberg P.R., Jones R.N., and The MYSTIC Program Study Group. Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials: report from the MYSTIC Program (2002) in North America. Diagn. Microbiol. Infect. Dis. 47 (2003) 365-372
19. Streit J.M., Jones R.N., Sader H.S., and Fritsche T.R. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). Int. J. Antimicrob. Agents 24 (2004) 111-118
20. Turner P.J. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection), a global overview. J. Antimicrob. Chemother. 46 (2000) 9-23
21. Turner P.J. Susceptibility of meropenem and comparators tested against 30,634 Enterobacteriaceae isolated in the MYSTIC Programme (1997-2003). Diagn. Microbiol. Infect. Dis. 50 (2004) 291-293